Inogen Inc (INGN) Director Sells $385,560.00 in Stock

Inogen Inc (NASDAQ:INGN) Director Loren L. Mcfarland sold 2,125 shares of Inogen stock in a transaction dated Friday, May 11th. The shares were sold at an average price of $181.44, for a total transaction of $385,560.00. Following the sale, the director now owns 3,114 shares in the company, valued at $565,004.16. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Shares of NASDAQ INGN opened at $172.60 on Wednesday. Inogen Inc has a 1-year low of $83.26 and a 1-year high of $189.76. The stock has a market capitalization of $3.76 billion, a price-to-earnings ratio of 131.76, a P/E/G ratio of 4.48 and a beta of 1.01.

Inogen (NASDAQ:INGN) last announced its earnings results on Monday, April 30th. The medical technology company reported $0.48 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.29 by $0.19. Inogen had a net margin of 9.36% and a return on equity of 14.81%. The company had revenue of $79.05 million during the quarter, compared to the consensus estimate of $63.86 million. During the same period in the previous year, the firm posted $0.27 earnings per share. The company’s revenue was up 50.6% on a year-over-year basis. sell-side analysts anticipate that Inogen Inc will post 1.76 EPS for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in INGN. California Public Employees Retirement System raised its stake in shares of Inogen by 31.2% in the third quarter. California Public Employees Retirement System now owns 26,498 shares of the medical technology company’s stock worth $2,520,000 after acquiring an additional 6,298 shares during the last quarter. Louisiana State Employees Retirement System raised its stake in shares of Inogen by 7.2% in the fourth quarter. Louisiana State Employees Retirement System now owns 7,400 shares of the medical technology company’s stock worth $881,000 after acquiring an additional 500 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of Inogen by 3.0% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 79,600 shares of the medical technology company’s stock worth $9,479,000 after acquiring an additional 2,327 shares during the last quarter. Acadian Asset Management LLC raised its stake in shares of Inogen by 31.5% in the fourth quarter. Acadian Asset Management LLC now owns 6,980 shares of the medical technology company’s stock worth $832,000 after acquiring an additional 1,674 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC raised its stake in shares of Inogen by 1,000.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,100 shares of the medical technology company’s stock worth $130,000 after acquiring an additional 1,000 shares during the last quarter. 99.23% of the stock is owned by institutional investors.

Several equities analysts recently issued reports on the stock. JPMorgan Chase lifted their price target on shares of Inogen from $150.00 to $180.00 and gave the company an “overweight” rating in a report on Tuesday, May 1st. Leerink Swann reissued an “outperform” rating and set a $170.00 price target (up from $150.00) on shares of Inogen in a report on Tuesday, May 1st. ValuEngine raised shares of Inogen from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. Zacks Investment Research raised shares of Inogen from a “hold” rating to a “buy” rating and set a $131.00 price target for the company in a report on Tuesday, February 13th. Finally, BidaskClub raised shares of Inogen from a “sell” rating to a “hold” rating in a report on Wednesday, January 24th. One analyst has rated the stock with a hold rating, three have issued a buy rating and three have issued a strong buy rating to the company. Inogen presently has an average rating of “Buy” and an average price target of $178.00.

Inogen Company Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply